Creating a strategy for targeting various types of cancer cells by combining FDA-approved drugs that are already used to treat non-cancer diseases.

Description :

In recent years, the strategy of drug repositioning has gained significant momentum. Compelling evidence indicates that identifying potential "off" targets of known drugs can not only help in mitigating severe side effects but also substantially reduce the estimated cost of $800 million and the 10–17 years typically required for drug development. Furthermore, this approach holds promise for repurposing existing drugs for new therapeutic applications. To validate this hypothesis, we will assess the efficacy of various FDA-approved drugs in inhibiting different cancer cell lines, including Breast, Ovarian, Prostate, Pancreatic, Lung, and Glioblastoma. This evaluation will determine if drug combination toxicity on cancer cells results in beneficial or adverse synergy. Through the optimization of our drug combinations, our objective is to accelerate the development of treatments that can significantly improve patient care.